611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Researchers ID Microbiome Genes Tied to AsthmaPlasma Rich in Growth Factors May Promote Hair RegenerationBest Practice Advice Issued for Hep B Vaccination, ScreeningIs a Common Shoulder Surgery Useless?NAFLD Linked to Smaller Total Cerebral Brain VolumeSalivary miRNAs Can ID Duration of Concussion SymptomsHigh Salt Intake Impacts Gut MicrobiomeSevere Psoriasis May Make Diabetes Increasingly LikelyNAFLD Linked to Increased Cancer Incidence RateSpinal Cord Stimulation May Reduce Neuropathic PainBrain Glucose Responses Diminish With Diabetes, ObesityMany Health Care Providers Work While SickIntensive BP Control Lacks Benefit in Chronic Kidney DiseaseGulf War Illness, Chronic Fatigue Syndrome Are Distinct Disorders: Study'Boomers' Doing Better at Avoiding Eye Disease of AgingAHA: Supervised Exercise Ups 6-Minute Walking Distance in PADAccurate Diagnosis Seen With Photographs of Skin ConditionsModel Predicts Development of Chronic Kidney DiseaseNew Hemophilia Treatment Stems Bleeding EpisodesHealth Tip: If There's a Wildfire NearbyPeanut Patch Found Safe, Effective for Treating AllergiesWhy a Headache Feels So DrainingStaying Active May Lower Odds for GlaucomaHow to Do a Skin Cancer Body CheckCan Treating Gum Disease Keep Blood Pressure in Line?AHA/ACA Present New Blood Pressure GuidelinesAAO: Higher Exercise Intensity Tied to Reduced Risk of GlaucomaAAO: Intranasal Tear Neurostimulator Safe for Dry EyeOutcomes for Atrial Fibrillation Similar With Dabigatran, WarfarinOutbreaks Linked to Drinking Water Mainly Due to LegionellaIs Low-Dose Aspirin Right for You After Surgery?Swings in Blood Pressure Can Pose Long-Term DangersAHA: Acetylcysteine, Sodium Bicarbonate Don't Cut Renal RiskBinge-Watchers, Beware: Long TV Time Poses Clot RiskObesity to Blame for Epidemic of Knee Dislocations, ComplicationsThe Heart Risks of a Desk JobCould Fish Oil, Vitamin D Help Ease Lupus?Smog May Harm Your Bones, TooOverlapping Surgery Appears Safe in Neurosurgical ProceduresAdding Exercise to Compression Therapy Promising for Leg UlcersRisk of End-Stage Renal Disease Low With Type 1 DiabetesHealth Tip: What's Healthy Blood Pressure?'Old' Lungs May Be Good Transplant OptionsHPV Vaccine Linked to Drop in Cases of Rare Childhood DiseaseNeurologic Abnormalities Identified After West Nile VirusSodium Oxybate Promising for Parkinson's, Daytime SleepinessDrop in Incidence of End-Stage Renal Disease Due to DiabetesThese Foods May Help Ease Rheumatoid Arthritis PainWhat Really Works to Fight a Stubborn Cough?West Nile's Long-Term Bite: Impact on Brain May Last Years
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Reduced Asthma Exacerbations Seen With Tezepelumab


HealthDay News
Updated: Sep 7th 2017

new article illustration

THURSDAY, Sept. 7, 2017 (HealthDay News) -- For patients with uncontrolled asthma despite treatment with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids, tezepelumab is associated with a significant reduction in asthma exacerbations, according to a study published online Sept. 6 in the New England Journal of Medicine.

Jonathan Corren, M.D., from the University of California in Los Angeles, and colleagues conducted a phase 2, randomized, double-blind trial comparing subcutaneous tezepelumab at three dose levels with placebo over a 52-week treatment period. The annualized rate of asthma exacerbations at week 52 was measured as the primary end point.

The researchers found that annualized asthma exacerbation rates at week 52 were 0.26, 0.19, and 0.22, respectively, with use of tezepelumab at a dose of 70 mg every four weeks (low dose, 145 patients), 210 mg every four weeks (medium dose, 145 patients), or 280 mg every two weeks (high dose, 146 patients), compared with 0.67 in the placebo group (148 patients). Compared with the placebo group, exacerbation rates were 61, 71, and 66 percent lower, respectively. Regardless of blood eosinophil counts at enrollment, results were similar. All tezepelumab groups had higher prebronchodilator forced expiratory volume in one second at week 52 compared with the placebo group.

"Among patients treated with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids, those who received tezepelumab had lower rates of clinically significant asthma exacerbations than those who received placebo," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including MedImmune (a member of the AstraZeneca group) and Amgen, which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)